VTR(300381)2025-04-18 13:20Financial Performance - The company's operating revenue for 2024 was CNY 826,201,215.91, representing a 3.79% increase compared to CNY 796,021,979.23 in 2023[22]. - Net profit attributable to shareholders for 2024 was CNY 31,091,854.42, a significant increase of 389.23% from a loss of CNY 10,749,720.98 in 2023[22]. - The net profit after deducting non-recurring gains and losses was CNY 5,984,339.22, up 130.35% from a loss of CNY 19,720,379.05 in the previous year[22]. - Basic earnings per share for 2024 were CNY 0.0634, compared to a loss of CNY 0.0219 in 2023, marking a 389.50% improvement[22]. - The company's total revenue for Q4 2023 was $217.75 million, showing an increase from $211.22 million in Q3 2023[24]. - The net profit attributable to shareholders for Q4 2023 was -$11.71 million, a significant decline from $1.02 million in Q3 2023[24]. - The net cash flow from operating activities in Q4 2023 was -$25.03 million, compared to $41.98 million in Q3 2023[24]. - The company's revenue for 2024 reached 826 million yuan, representing a year-on-year growth of 3.79%[51]. - The net profit attributable to shareholders was 31.09 million yuan, marking a turnaround from losses[45]. Assets and Liabilities - The total assets at the end of 2024 were CNY 2,948,587,167.07, a decrease of 4.73% from CNY 3,094,935,260.92 at the end of 2023[22]. - Cash and cash equivalents decreased by 65.44% to 28,671,223.66 due to a lack of continued investment in financial products[53]. - The company's total liabilities decreased by 100.00% in estimated liabilities, mainly due to the change in accounting method for minority equity in a German subsidiary[76]. Investment and Projects - The company has multiple new projects focused on biological enzyme preparations, biosynthetic products, and plant extracts, supported by national policies[6]. - The company completed the acquisition of Enzymes GmbH for €3.01 million, representing 49% of the equity stake, funded by internal resources[84]. - The company reported a total investment of €22.56 million in the food-grade enzyme project, with a cumulative actual investment of €282.38 million as of the reporting period[86]. - The company is undertaking a project to enhance intelligent manufacturing with an investment of €8.29 million, which is also not yet operational[86]. Research and Development - The company has made significant advancements in the development of over 50 research projects, including high-temperature resistant enzymes and various other enzyme products[46]. - The company has published over 600 papers and holds 60 invention patents, indicating strong research capabilities[138]. - The company has participated in over 20 national and industry standards, showcasing its influence in the sector[138]. - R&D investment increased to approximately 109.32 million yuan in 2024, representing 13.23% of operating revenue, up from 12.54% in 2023[67]. Market Expansion and Strategy - The company plans to continue expanding its overseas market presence despite geopolitical risks and economic uncertainties[4]. - The company has established a comprehensive overseas marketing network, including a subsidiary in Germany and an office in Russia, enhancing its international brand image[46]. - The company is actively expanding its market presence in Southeast Asia, South America, and the Middle East, while maintaining growth in Europe, Russia, and North America[47]. - The company aims to become a leading enterprise in the animal nutrition and health industry in China[44]. Corporate Governance - The company has established a governance structure that complies with relevant regulations, including the Company Law and the Shenzhen Stock Exchange rules, ensuring effective internal control and risk management[124]. - The board of directors consists of 7 members, including 3 independent directors, and operates through specialized committees to ensure compliance and effective decision-making[125]. - The company emphasizes transparency in information disclosure, ensuring timely and accurate communication with investors through multiple channels[126]. Environmental Responsibility - The company has invested approximately 8.8874 million yuan in environmental governance and protection for the year 2024[185]. - The company has paid an environmental protection tax of 114,000 yuan during the reporting period[185]. - The wastewater treatment capacity of the company is 4,000 tons per day, utilizing a treatment process of "pre-treatment + anaerobic + AMOXP + A/O + secondary sedimentation"[182]. - The company has established an emergency response plan for sudden environmental incidents, which has been filed with local environmental protection authorities[184]. Employee and Management - The total number of employees at the end of the reporting period was 1,102, with 388 in the parent company and 714 in major subsidiaries[159]. - The company has established a performance evaluation system for senior management, ensuring that employee income is closely linked to work performance[160]. - The company has implemented a training plan focusing on various themes, including industry, management, production, and R&D, to enhance employee competencies[161]. Shareholder Relations and Dividends - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares, which is inclusive of tax[168]. - The total cash dividend distribution amounts to RMB 48,017,386.10, with a payout ratio of 100% of the profit distribution[168]. - The company has not issued any bonus shares or increased capital from reserves during the reporting period, maintaining a focus on cash dividends[167].